Reuters exclusively reports Lilly hit by staff accusations, FDA scrutiny at COVID drug factories | Reuters News Agency
Health

Reuters exclusively reports Lilly hit by staff accusations, FDA scrutiny at COVID drug factories

Reuters exclusively reported that Eli Lilly & Co employees have accused a factory executive of altering documents required by government regulators in an effort to downplay serious quality control problems at the U.S. plant producing the drugmaker’s COVID-19 treatment. An internal complaint asserts that an official at the company rewrote findings by technical experts to make the conclusions appear more favorable to the company. 

Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Regions: North America
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Important Regional Story
FILE PHOTO: FILE PHOTO: FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021.  REUTERS/Mike Segar/File Photo/File Photo/File Photo
Sign up for email updates
Subscribe
Sign up for email updates